Lutetium chloride
As of the edition of 20 October 2026, Lutetium chloride is a small molecule: withdrawn from the market in 2026; acts on FOLH1, SSTR1 and SSTR2 and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2026
- Kind
- Small molecule
- Brand name
- EndolucinBeta
- First approved
- 6 July 2016 (EU)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Shine; 4 holders in all
- Withdrawn from market
- 16 January 2026 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Lutetium chloride.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| ITM Medical Isotopes | Applicant | 2016 to now |
| Billev Pharma Aps | Later holder | 2022 to now |
| Eckert & Ziegler Radiopharma | Later holder | 2024 to now |
| Shine | Later holder | 2026 to now |